Zhang Li Qin, Heruth Daniel P, Ye Shui Qing
Department of Pediatrics, Children's Mercy Hospitals and Clinics, University of Missouri School of Medicine, Kansas City, MO 64108, USA.
J Bioanal Biomed. 2011 Jan 7;3:13-25. doi: 10.4172/1948-593X.1000038.
Nicotinamide phosphoribosyltransferase (NAMPT) was first reported as a pre-B-cell colony enhancing factor in 1994 with little notice, but it has received increasing attention in recent years due to accumulating evidence indicating that NAMPT is a pleiotropic protein such as a growth factor, a cytokine, an enzyme and a visfatin. Now, NAMPT has been accepted as an official name of this protein. Because of NAMPT's multiple functions in a variety of physiological processes, their dysregulations have been implicated in the pathogenesis of a number of human diseases or conditions such as acute lung injury, aging, atherosclerosis, cancer, diabetes, rheumatoid arthritis and sepsis. This review will cover the current understanding of NAMPT's structure and functions with an emphasis on recent progress of nicotinamide phosphoribosyltransferase's pathological roles in various human diseases and conditions. Future directions on exploring its Terra incognita will be offered in the end.
烟酰胺磷酸核糖转移酶（NAMPT）于1994年首次被报道为前B细胞集落增强因子，但当时并未引起太多关注。近年来，由于越来越多的证据表明NAMPT是一种多效性蛋白，如生长因子、细胞因子、酶和内脂素，它受到了越来越多的关注。现在，NAMPT已被公认为该蛋白的正式名称。由于NAMPT在多种生理过程中具有多种功能，其失调与许多人类疾病或病症的发病机制有关，如急性肺损伤、衰老、动脉粥样硬化、癌症、糖尿病、类风湿性关节炎和败血症。本综述将涵盖目前对NAMPT结构和功能的理解，重点是烟酰胺磷酸核糖转移酶在各种人类疾病和病症中的病理作用的最新进展。最后将提供探索其未知领域的未来方向。
